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INTRODUCTION
To date, the great majority of disease modifying clinical trials in 
Alzheimer’s disease (AD) have not succeeded despite promising 
preclinical data. The potential reasons for this failure is that; (1) the 
agents so trialled are aimed at the wrong pathological target; (2) 
there is a loss of target engagement; (3) the treatment is given too 
late in the disease course; or (4) the previous models are affected 
by the effects of aging beyond AD pathogenesis [1, 2]. 
Conventional AD models are mainly based on the overexpres-
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sion of AD-related genes which overemphasizes by its very nature 
certain pathogenic pathways, thereby limiting the clinical transla-
tion of such approaches. In particular, the most popular mouse 
models of AD are based on the overexpression of each or combi-
nations of amyloid precursor protein (APP), Presenilin 1 (PSEN1), 
or Presenilin 2 (PSEN2), all of which result in amyloid beta (Aβ) 
plaques and inflamation. However, these animals rarely show any 
neurodegeneration in the brain by the time of death [3, 4]. On the 
other hand, AD patients are known to have a very long preclini-
cal phase to their manifest illness which can exceed 10~20 years, 
during which time aging is known to affect AD pathophysiology 
and the subsequent neurodegernation. Therefore, to eliminate or 
minimize the effect of aging, we focused on autosomal dominant 
AD (ADAD) patients, who develop AD symptoms in middle age. 
In addition, we employed an induced pluripotent stem cell (iPSC)-
based technology to model AD pathophysiology, in which the 
effect of aging is not normally reflected during reprogramming 
process [5]. To do this, we generated iPSC lines from an AD pa-
tient with a known PSEN1 mutation (Glu120Lys; PS1-E120K) and 
from an elderly normal subject, as a control. The main purpose of 
this study was to investigate whether the PS1-E120K iPSC-derived 
neurons manifest the cardinal pathological features of AD, includ-
ing aggregation of Aβ and tau. Given that the effect of aging is not 
normally refected in iPSCs, we anticipated that the iPSC model of 
this AD patient would better reveal the pathogenic conesequences 
of a PS1-E120K mutation, with no or only limited effects from ag-
ing.
Using this approcah, we have demonstrated that the level of ex-
tracellular deposition of Aβ dramatically increased in PS1-E120K 
iPSC-derived neurons, compared with the control iPSC-derived 
neurons. Furthermore, we showed that PS1-E120K iPSC-derived 
neurons expressed high levels of phosphorylated tau along with 
abnormal mitochondrial activity and defective autophagy.
MATERIALS AND METHODS
Enrollment of participants
The patient met the criteria for AD as recommended by the 
National Institute on Aging–Alzheimer’s Association [6] and the 
normal elderly subject fulfilled the criteria of a normal elderly 
control as defined by Christensen [7]. We performed detailed neu-
ropsychological tests, MRI, [18F]-Florbetaben or [11C]-Pittsburgh 
compound B (PIB) amyloid PET scans, and blood draw for iPSC 
generation from each participant. The Institutional review board 
of CHA University (1044308-201612-BR-031-02), Samsung 
Medical Center (2013-03-087), and Asan Medical Center (2015-
0699) approved the study protocol, and informed written consent 
was obtained from each participant. All methods were performed 
in accordance with the relevant guidelines and regulations.
Generation of iPSC lines
Mononuclear cells (MNCs) were isolated freshly from the pe-
ripheral blood of the AD patient and normal subject using the 
Ficoll-PaqueTM PLUS method (GE Healthcare, USA). Isolated 
peripheral-derived MNCs (PBMCs) were cultured for 4 days in 
MNC media containing 50 ng/ml interleukin-6 (IL-6), 50 ng/ml 
stem cell factor (SCF), 10 ng/ml thrombopoietin (TPO), 20 ng/ml 
Flt3 ligand (Flt-3L), 20 ng/ml interleukin-3 (IL-3), and 10 ng/ml 
granulocyte colony-stimulating factor (G-CSF) (all from WAKO, 
Japan) in StemFit AK03 medium (kindly provided by Ajinomoto, 
Japan). The MNCs were then infected with SeVdp (KOSM) 302L 
at MOI of 3~10 [8] and transferred into 6-well dishes coated 
with iMatrix-511 (Matrixome, Japan). From the next day, 500 ul 
of StemFit AK03 medium was added every day for 4 days, after 
which the medium was fully changed every other day until iPSC-
like colonies emerged. Sub-culturing and expansion of the cells 
was then undertaken until the generated iPSCs became stable for 
characterization and storage, normally at passage 10. 
Karyotyping and genotyping 
Karyotyping was performed using a GTG-banding analysis (Ko-
rea Research of Animal Chromosomes, Korea). The iPSC pellets 
were incubated in lysis buffer containing 100 mM Tris-HCl (pH 
8.0), 50 mM EDTA, 0.2% SDS, 200 mM NACL and 200 ug/ml Pro-
teinase K for 3 hr at 55oC. Genomic DNA was isolated by isopro-
pyl alcohol precipitation, followed by a 70% ethanol washing step. 
Genotyping of the PS1-E120K single nucleotide mutation was 
performed by PCR amplification of isolated iPSC genomic DNA, 
followed by DNA sequencing (Cosmo Genetech, Korea). The PS1 
gene was amplified by PCR using the following primers (forward 
primer: GTA GAA TCT ATA CCC CAT TC; reverse primer: TCA 
CCT TAT AGC ACC TGT AT).
Reverse transcription- polymerase chain reaction (RT-PCR) 
and Quantitative-PCR (Q-PCR)
Total RNAs were manually isolated using the TRIzol reagent (Life 
Technologies) lysis and isopropyl alcohol precipitation. Comple-
mentary DNAs (cDNAs) were synthesized using the cDNA 
synthesis Kit (Cosmo Genetech, Korea). RT-PCR amplification 
was done in a final volume of 20 ul containing 200 ng/ul cDNA 
for each sample. Primers were used as follows: GAPDH (forward 
primer: TGA CCA CAG TCC ATG CCA TCA CTG C; reverse 
primer: GTC ATA CCA GGA AAT GAG CTT GAC A); OCT4 
(forward primer: CTG AAG CAG AAG AGG ATC AC; reverse 
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primer: GAC CAC ATC CTT CTC GAG CC); NANOG (forward 
primer: TTC TTG ACT GGG ACC TTG TC; reverse primer: 
GCT TGC CTT GCT TTG AAG CA); SOX2 (forward primer: 
GCT GCA AAA GAG AAC ACC AA; reverse primer: CTT CCT 
GCA AAG CTC CTA CC); LIN28 (forward primer: CAC CAT 
GGG CTC CGT GTC CAA CCA GCA G; reverse primer: TCA 
ATT CTG TGC CTC CGG GAG CAG GGT AGG). Q-PCR anal-
ysis was performed using TB GreenTM Premix Ex TaqTM (TaKaRa) 
with 100 ng/ul cDNA for each sample. Primers were used as fol-
lows: PSEN1 (forward primer: ACA GAG TTA CCT GCA CCG 
TTG T; reverse primer: GCT ATA AGG TCA TCC ATG CCT G); 
DRP1 (forward primer: ATG TTG CAT CTG GAG GTG GT; re-
verse primer: CGT GAA CCT GCT AGA TGT GC); Fis1 (forward 
primer: CAG TTT GAG TAC GCC TGG TG; reverse primer: 
CCG GCT CAA GGA ATA CGA GA); Mfn1 (forward primer: 
CTG GCT GTC TTG TAC GTG TG; reverse primer: CAA GGT 
GAA TGA GCG GCT TT); Mfn2 (forward primer: GAC CCC 
GTT ACC ACA GAA GA; reverse primer: GCT CTG GGA CAA 
AGT TCT GC).
Sendai virus detection PCR
After total RNA isolation and cDNA synthesis, Sendai virus de-
tection RT-PCR was performed using a final volume of 20 ul with 
a 200 ng/ul concentration for each sample. Primers were used as 
follows: SeVdp NP (forward primer: AGA CCC TAA GAG GAC 
GAA GAC AGA; reverse primer: ACT CCC ATG GCG TAA 
CTC CAT AG) for detecting the nucleoprotein (NP) of Sendai 
virus vector (SeVdp) [9].
Mycoplasma detection PCR
After genomic DNA isolation as described above, we detected 
the mycoplasma contamination in cell culture using the PCR-
based e-MycoTM VALiD Mycoplasma detection Kit (iNtRON, Ko-
rea). PCR was done using a final volume of 20 ul containing 100 
ng/ul of each sample [9, 10].
In Vitro differentiation
Human iPSCs were harvested using a 0.5% TrypLE Select (Ther-
moFisher) treatment and used for embryoid body (EB) formation. 
Detached cells were transferred into 96-well NunclonTM SpheraTM 
Microplate (ThermoFisher) that includes DMEM/F12 medium 
containing 20% Knockout serum replacement (KSR; Life Technol-
ogy), 0.1 M nonessential amino acids (NEAA), 0.1 M 2-mercap-
toethanol (Life Technologies) and 0.1 antibiotic-antimycotic solu-
tions (ThermoFisher). The medium was changed every other day 
and the EBs were plated onto 0.2% gelatin-coated glass coverslips 
at day 8. EBs were then allowed to differentiate spontaneously for 
an additional 8 days. 
Cortical neuronal differentiation 
For the cortical neuronal differentiation, iPSCs were dissociated 
into single cells and quickly re-aggregated in a 96-well NunclonTM 
SpheraTM Microplate (ThermoFisher). The EBs were cultured in 
DMEM/F12 containing 20% knockout serum replacement (KSR), 
0.1 M nonessential amino acids (NEAA), 0.1 M 2-mercaptoetha-
nol, 0.1% antibiotic-antimycotic solutions (all from ThermoFish-
er), 10 uM SB431542 (Reagent Direct) and 10 uM LDN 193189 
(Reagent Direct) for neural induction for 8 days. These neural 
induced EBs were dissociated using AccutaseTM (Stem Cell Tech-
nologies) and were seeded onto 15 ug/ml poly-L-ornithine (Sigma) 
and 5 ug/ml laminin (Sigma)-coated dishes. Once neural precur-
sor cells (NPCs) were formed, they were cultured in DMEM/F12 
media containing 0.1 M nonessential amino acids (NEAA), 0.1 M 
2-mercaptoethanol, 0.1 antibiotic-antimycotic solutions, 1% D-
Glucose (Life Technologies), 1% B27 supplement without vitamin 
A (all from ThermoFisher), 200 mM L-Glutamine (Sigma), and 20 
ng/ml basic fibroblast growth factor (bFGF; PeproTech Korea). Fi-
nally, NPCs were differentiated into cortical neurons for 10 weeks 
in Neurobasal A medium containing 1% B27 supplement without 
vitamin A, 1x Glutamax (all from ThermoFisher), 10 ng/ml brain-
derived neurotrophic factor (BDNF), 10 ng/ml glial cell-derived 
neurotrophic factor (GDNF), 10 ng/ml nurotrophin-3 (NT3) (all 
from PeproTech Korea) on PLO/laminin-coated dishes [10].
Immunocytochemistry
The cells were fixed with 4% paraformaldehyde (PFA) for 15 
min at room temperature (RT). Fixed cells were permeabilized 
and washed with TPBS containing 0.1% TritonX-100 (Sigma) in 
phosphate-buffered saline (PBS) and blocked with 5% normal 
horse serum (Vector Labs) for 30 min at RT. Afterwards, they were 
incubated with primary antibodies in blocking solution overnight 
with gentle rocking at 4oC. After washing three times with TPBS, 
they were incubated with secondary antibodies (ThermoFisher) 
for 90 min at RT, and then were counterstained using DAPI for 
15 min. All fluorescence images were captured by confocal mi-
croscopy (TCSSP5II, Leica). The following primary antibodies 
were used: anti-OCT4 (1:200, Santa Cruz), anti-SOX2 (1:200, Mil-
lipore), anti-NANOG (1:200, R&D Systems), anti-SSEA-4 (1:100, 
Developmental Studies Hybridoma Bank)), anti-TRA-1-81 (1:100, 
CHEMICON), Tuj1 anti-tubulin beta III isoform (1:200, Mil-
lipore), anti-SMA (1:100, DAKO); anti-AFP (1:100, DAKO), anti-
Nestin (1:200, R&D Systems), anti-Musashi (1:200, Millipore), an-
ti-Map2 (1:200, Millipore), anti-TBR1 (1:100, Abcam), anti-CTIP2 
(1:100, Abcam), 6E10 anti-Amyloid β (1:500, Covance), AT8 anti-
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p-tau (1:1000, ThermoFisher), anti-ChAT (1:200, Millipore) and 
anti-LC3B (1:500, Cell Signaling).
Extracellular and intracellular amyloid-β ELISA 
Conditioned media (CM) were collected from cultured neuronal 
cells (1×105) at 48 hours after the last medium change from 6 and 
10 weeks of differentiation. The pellets of iPSC-derived neurons 
were resuspended in RIPA buffer (Biosesang) containing protease 
inhibitors (ThermoFisher) and phosphatase inhibitors (Thermo-
Fisher). Then they were chilled on ice for 30 min and sonicated. 
The supernatants were collected after centrifugation at 13,000 rpm 
for 30 min to remove membrane lipids. Protein concentration was 
determined using a BCA Protein Assay Kit (ThermoFisher). In-
tracellular Aβ42 and Aβ40 were measured in a total of 1 µg proteins 
from 10 week-differentiated neurons. Aβ40 and Aβ42 levels were 
measured using the human Aβ40 and Aβ42 ELISA Kit according to 
the manufacture’s instruction (IBL). ELISA plate reader (BioTek) 
was used to quantify Aβ40 and Aβ42 levels.
Western blot analysis
Cultured neurons in 6-well plates were harvested at 10 weeks of 
differentiation as cell pellets and were resuspended in RIPA buffer 
(BIOSESANG) containing protease inhibitors (ThermoFisher) 
and phosphatase inhibitors (ThermoFisher). They were then 
chilled on ice for 30 min and sonicated. The supernatants were 
collected after centrifugation at 13,000 rpm for 30 min to remove 
membrane lipids. Protein concentration was determined using a 
BCA Protein Assay Kit (ThermoFisher), and 25 ug of protein for 
each sample was electrophoresed on 8% or 12% gels. The separated 
samples were transferred onto a PVDF membrane and incubated 
with target antibodies. Protein bands were visualized by Immobi-
lon Western (Millipore) and were detected using Chemi-Doc (Bio-
Rad). The following primary antibodies were used: Tau5 anti-tau 
(1:1,000, ThermoFisher), AT8 anti-p-tau (1:1,000, ThermoFisher), 
anti-OPA1 (1:1,000, Santa Cruz), anti-Mfn1 (1:1,000, Abcam), an-
ti-Mfn2 (1:1,000, Cell Signaling), anti-Drp1 (1:1,000, Cell Signal-
ing), anti-Fis1 (1:1,000, Santa Cruz), anti-Ub (1:4,000, Santa Cruz), 
anti-LC3B (1:1,000, Cell Signaling), anti-LAMP2 (1:1,000, Santa 
Cruz), anti-Beclin1 (1:1,000, Cell Signaling), p62 anti-SQSTM1 
(1:1,000, Santa Cruz), 4G8 anti-APP (1:500, Covance), anti-p-
Drp1 (Ser637, 1:1000, Cell Signaling) and anti-β-actin (1:10000, 
Santa Cruz).
Autophagy flux assay and Cyto ID live cell staining
For autophagy flux assay, we treated cells with 10 uM chloroquine 
(CQ) for 12 h, a compound known to interference the lysosomal 
function [11]. After 12 h, we used the CytoID® Green Autophagy 
Detection Kit (Enzo Life Sciences Inc., Cat. No, ENZ-51031-K200) 
to detect the autophagic vesicles in live cells. Induction of autopha-
gic flux can be visualized by enhanced accumulation of autophagic 
vesicles when lysosomal function is inhibited. CytoID green was 
co-stained with DAPI and the fluorescence images were captured 
using a confocal microscopy (TCSSP5II, Leica). The quantifica-
tion for the number and size of autophgic vesicles were performed 
using Image J (particle analysis plugin).
Statistical analysis
All statistical analyses were performed using a one-factor analy-
sis of variance (ANOVA) followed by a Fisher’s LSD (Least Signifi-
cant Difference) using the Statistical Analysis System (Enterprise 
4.1, SAS Korea, Seoul, Korea). Significance was accepted at the 95% 
probability level. Data in graphs are presented as mean±SEM. p-
value<0.05 (*), p-value<0.01 (**) and p-value<0.001 (***).
RESULTS
Clinical characteristics of the patient
The patient was a 38-year-old woman who visited the outpatient 
clinic of Samsung Medical Center, Seoul, Korea. She had progres-
sive memory impairment over a course of five years, which even-
tually resulted in disturbance of her daily life. She had 16 years of 
education and had no history of medical illness. A mildly spastic 
gait was noticed by her husband 6 months prior to presentation. 
Neurological examination revealed cerebellar dysfunction, includ-
ing limb and truncal ataxia, dysdiadochokinesia, cerebellar dysar-
thria, and ocular abnormalities, such as overshooting saccades and 
Table 1. Neuropsychological test results of the patient











































K-BNT, Korean version of the Boston Naming Test; RCFT, Rey-Osterrieth 
Complex Figure Test; SVLT, Seoul Verbal Learning Test; COWAT, Con-
trolled Oral Word Association Test.
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saccadic intrusions during smooth pursuit eye movements. She 
also had bilateral spasticity in her legs and bradykinesia in both 
upper extremities. She demonstrated global cognitive problems 
with deficits in verbal and visual memory, language, and visuo-
spatial functions with relative sparing of attention and frontal-
executive function (Table 1).
The patient had a family history of dementia and ataxia (Fig. 
1A). Her grandmother (I:2 in Fig. 1A) had developed a late-onset 
dementia during the seventh decade of life and died ten years after 
the diagnosis. Her cousin (III:2 in Fig. 1A) was diagnosed with 
late-onset cerebellar ataxia at the age of 54 and died at 62 years of 
age due to aspiration pneumonia without evidence of cognitive 
impairment. Brain MR images of her cousin (III:2) demonstrated 
severe cerebellar atrophy (Fig. 1B) without prominent atrophy of 
the medial temporal lobes. Brain MRI of our patient revealed gen-
eralized cortical atrophy along with atrophy in the bilateral medial 
temporal lobes and cerebellum (Fig. 1C). Laboratory studies of the 
patient, including 24-hour urine copper levels were unremark-
able. Given the tentative diagnosis of dementia associated with a 
familial cerebellar ataxia, genetic evaluations for spinocerebellar 
ataxia (SCA, 1, 2, 3, 6, 7, 8, 12, 17, 27), dentatorubral-pallidoluysian 
atrophy (DRPLA), and late-onset Friedreich’s ataxia (Frataxin 
gene) were performed and shown to be negative. Huntingtin gene 
test was negative. Given the diagnosis of early onset dementia 
with spastic paraparesis, a genetic work-up for a Presenilin muta-
tion was performed [12], and a mutation in the PSEN1  gene (a 
transition from G (358th codon) to A, resulting in a change from 
glutamate to lysine at codon 120 (Glu120Lys; PS1-E120K)) was 
detected. For the control iPSC generation, blood samples were 
obtained from a cognitively normal elderly man aged 72, who ful-
filled the criteria for being a normal elderly person [7].
Pittsburgh compound-B (PiB) positron emission tomography 
(PET) imaging of the patient revealed a deposition of Aβ in the 
striatum as well as in the bilateral frontal lobes, posterior cingulate 
cortices, and precuneus (Fig. 1D). These PiB-PET image findings 
of the patient are compatible with previous reports of familial AD 
with spastic paraparesis caused by PSEN1 mutations [13, 14]. The 
PiB-PET images of our patient did not reveal amyloid deposition 
in the cerebellum as shown in some previous studies [13, 15]. The 
MRI and 18F-Florbetaben amyloid PET images of the normal el-
derly subject were in normal range. 
Generation of iPSC lines and cortical neuronal differentiation
Isolated MNCs were reprogrammed using Sendai virus vector 
(SeVdp) which expresses four reprogramming factors (OCT3/4, 
SOX2, cMYC, and KLF4) [9]. In our iPSC generation procedure, 
we normally pick more than three individual clones and select 
the best growing clone among them for further analyses, includ-
ing neuronal differentiation experiments. Although the effects of 
PS1-E120K mutation on Aβ deposition have been studied in the 
brains of familial AD patients previously [16, 17], the pathologi-
cal features of the patients are less known at cellular levels. For 
this reason, we generated an iPSC line from AD patient carrying a 
mutation for PS1-E120K using iPSC technology for the first time. 
Control and PS1-E120K mutation iPSC lines exhibited the typical 
expression of undifferentiated pluripotent stem cell markers, such 
as OCT4, SOX2, SSEA4 and TRA-1-81 (Fig. 2A, B). Genotyping of 
the established iPSC lines was confirmed using a conventional se-
quencing method (Fig. 2C). The differentiation potential of iPSC 
lines was assessed in vitro by three-germ layer marker expression 
(Fig. 2D). Control and PS1-E120K mutation iPSC lines did not 
carry a SeV integration (Fig. 2E) and were not contaminated by 
mycoplasma (Fig. 2F, G).
To characterize the cortical neurons derived from each iPSC line, 
we developed a modified cortical neuron differentiation protocol, 
based on previously published procedures (Fig. 3A) [10]. Differ-
entiated cells expressed general neuronal markers (i.e. , Tuj1 and 
Map2), cholinergic marker (i.e. , ChAT), as well as cortical neuron 
markers (i.e. , TBR1 and CTIP2; Fig. 3B, C). We observed high 
levels of neuronal differentiation in our experiments, and the fol-
lowing is the relative percentage of each neuronal cell type (con-
trol vs . PS1-E120K iPSC-derived neurons): TUJ1 (86.79%±3.37 
vs . 82.41%±4.42) MAP2 (80.24%±2.47 vs . 80.45%±1.81), TBR1 
(61.29%±2.23 vs . 64.69%±3.47) and CTIP2 (59.65%±3.28 vs . 
49.40%±6.73). Among them, the percentage of TBR1/CTIP-
double positive neurons were relatively high (58.02%±4.43 vs . 
48.41%±6.93), indicating our cortical neuron differentiation was 
efficient. We also observed high levels of ChAT, a marker for cho-
linergic neurons (74.25%±6.69 vs. 81.20%±2.23). In most cases, no 
significant differences in the neuronal differentiation propensity 
was seen between control and PS1-E120K iPSC lines (Fig. 3D). 
In addition, there was no significant difference of PSEN1 gene 
expression in iPSC and iPSC-derived neurons (data not shown). 
Moreover, no significant difference in features associated with 
aging was observed between the two iPSC lines (i.e. , PS1-E120K 
iPSC from the 38 year-old AD patient vs . control iPSC from the 72 
year-old normal elderly subject).
Detection of Aβ secretion from the PS1-E120K iPSC-derived 
neurons 
To analyze the functional aspects of familial AD (PS1-E120K), 
we investigated Aβ secretion in the conditioned medium (CM) 
from the iPSC-derived neurons at 6 weeks and 10 weeks after dif-
ferentiation. We measured Aβ40 and Aβ42 levels 48 hr after the last 
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Fig. 1. Pedigree of the patient’s family and brain MR images of the cousin of the patient and MR and Pittsburgh compound-B (PiB) positron emission 
tomography (PET) images of the patient. (A) Pedigree of the patient. I-2: grandmother of the patient, dementia; III-2: cousin of the patient, late onset 
cerebellar ataxia; III-10: the patient, dementia, spastic paraparesis, cerebellar ataxia. (B) Fluid attenuated inversion recovery (FLAIR) MR images of the 
cousin show severe ponto-medullo-cerebellar atrophy without atrophy in the medial temporal lobes. (C) T2-weighted axial MR images of the patient 
(III-10 in the pedigree) showing atrophy bilaterally of the medial temporal lobes and prominent volume loss in the cerebellum with enlargement of the 
fourth ventricle. (D) Increased amyloid deposition in the bilateral striatum, frontal and posterior cingulate cortices, and precuneus, but not in the cer-
ebellum.
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Fig. 2. Generation of iPSCs from an AD patient harboring a PSEN1 (E120K) mutation, and an eldely normal subject. (A) Established iPSC lines from 
both control and PS1-E120K patient showing the expression of pluripotent stem cell markers, such as OCT4 (red), SOX2 (green), SSEA4 (red) and TRA-
1-81 (red). (B) Reverse transcription PCR (RT-PCR) showing the expression of pluripotency markers (OCT4, SOX2, NANOG, SSEA4 AND TRA-1-
81) in both iPSC lines. (C) Genomic DNA sequences showing the presence of the heterozygous E120K mutation (GAA to AAA) in the PSEN1 gene of 
the PS1-E120K -iPSC line. (D) Immunofluorescence analysis showing the potential of iPSC lines to form three germ layers, including ectoderm (type III 
β-tubulin [TUJ1], green), mesoderm (smooth muscle actin [SMA], green), and endoderm (α-fetoprotein [AFP], red). Scale bar: 100 µm. (E) Karyotype 
analysis of the control and PS1-E120K iPSC lines. (F) Reverse-transcription PCR analysis showing the absence of integration of the Sendai virus vectors. 
(G) PCR analysis showing no contamination by mycoplasma.
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Fig. 3. Cortical neuron differentiation of PS1-E120K- and control-derived iPSCs. (A) Schematic diagram showing our stepwise cortical neuronal dif-
ferentiation protocol. Control and PS1-E120K patient-derived iPSC lines were differentiated into neural precursor cells (NPC) using the Dual SMAD 
inhibition method. Afterwards, NPCs were treated with neurotrophic factors including BDNF, GDNF and NT3 to induce cortical neurons. (B) Immu-
nofluorescence analysis of control and PS1-E120K iPSC-derived NPCs, showing the expression of NPC markers, such as Nestin (green), SOX2 (red) and 
Musashi (green) with DAPI (blue). (C) Immunofluorescence analysis of control and AD-iPSC-derived cortical neurons (TUJ1 [red] and Map2 [green]). 
Cholinergic neurons (ChAT [red]) and cortical neurons (TBR1 [red] and CTIP2 [green]) at 10 weeks after differentiation were shown. (D) Ratios of 
each mature neuronal cell type relative to DAPI staining. Scale bar: 50 µm.
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medium change. Strikingly, PS1-E120K iPSC-derived neurons 
exhibited a dramatic increase in Aβ42 levels (over 2-fold) com-
pared with the control iPSC-derived neurons at both 6 weeks and 
10 weeks after differentiation (Fig. 4A). However, no difference in 
Aβ40 levels was detected (Fig. 4B). Importantly, the ratio of Aβ42/
Aβ40 was significantly increased (over 2-fold) in PS1-E120K 
iPSC-derived neurons (Fig. 4C) compared with the control iPSC-
derived line. Furthermore, intracellular Aβ42 levels and the ratio 
of Aβ42/Aβ40 was also significantly increased in PS1-E120K iPSC-
derived neurons (Fig. 4D~F). We also observed a marked increase 
in APP expression levels in PS1-E120K iPSC-derived neurons (Fig. 
4H and I). To detect the Aβ deposits, iPSC-derived neurons were 
stained with the anti-Aβ antibody 6E10 and 4G8 at 10 weeks of 
differentiation. Using a confocal microscopy we found a distinctive 
increase of extracellular Aβ deposits in PS1-E120K iPSC-derived 
neurons compared with the control iPSC-derived neurons (Fig. 
4G, H). Given the difference in ages when the blood was drawn to 
generate both iPSC-derived neurons, the current findings suggest 
that the accumulation of Aβ protein can be driven by the PS1-
E120K mutation beyond the effect of aging.
Elevated phosphorylated-tau levels in the PS1-E120K iPSC-
derived neurons
Tau protein normally exists as a soluble form in axons. However, 
as it becomes hyperphosphorylated, as in AD, it accumulates in 
dendrites and cell bodies [16, 17]. To analyze the phosphorylated 
tau (p-tau) levels in the iPSC-derived neurons, we performed west-
ern blot analyses using antibodies against AT180 (phosphorylated 
at Thr231), p-Tau (phosphorylated at Ser400, Thr403/Ser404), 
and Tau5 (total tau). Then, we found that there exist multi-bands 
indicative of fractions in AT8, AT180 and p-Tau and the protein 
expression of each was strongly increased in the PS1-E120K iPSC-
derived neurons compared with the control lines (Fig. 5A~F). 
These findings are in line with previous studies demonstrating 
that brain tissues from AD patients with severe Braak stages [18, 
19] and neural cells with PSEN1 and APP mutation showed mul-
tiple bands of p-tau (>50 kDa) compared with the controls [20]. 
We also found that there was an increase of total tau (Tau5) levels, 
which likely correlates with a robust increase in the aggregated tau 
fractions [20]. 
As we found the increase of fragmented tau in our PS1-E120K 
iPSC-derived neurons at 10 weeks of differentiation, we con-
ducted tau ELISA to detect soluble tau using conditioned medium. 
We found that PS1-E120K patient exhibited significant increases 
in soluble tau both at 6 and 10 weeks of differentiation (data not 
shown). To further investigate this p-tau accumulation at the cel-
lular level, we performed immunocytochemical analysis using 
an antibody against AT8 and found that, unlike in the control 
iPSC-derived neurons, AT8 expression in the PS1-E120K iPSC-
derived neurons was localized to the cell bodies (Fig. 5G~J). Taken 
together, these results show that there are high levels of p-tau (AT8) 
which localizes to the cell bodies in the PS1-E120K iPSC-derived 
neurons, compared with the control iPSC-derived neurons.
Impaired mitochondria fission and fusion protein levels in 
the PS1-E120K iPSC-derived neurons
Mitochondrial dysfunction is a prominent feature in AD [22, 
23]. Recent studies have reported that extracellular Aβ and phos-
phorylated tau could be attributed to the impaired balance of 
mitochondrial fission and fusion [6, 24]. To investigate whether 
mitochondria fission and fusion was impaired in our PS1-E120K 
iPSC-derived neurons, we measured the expression levels of mito-
chondria fission-related proteins, Drp1 (dynamin-related protein 
1), p-Drp1 (for the detection of inhibitory phosphorylation of 
Drp1 at Ser637) and Fis1 (mitochondrial fission 1 protein); and 
fusion-related protein OPA1 (optic atrophy 1 gene protein), Mfn1 
(membrane proteins mitofusin 1) and Mfn2 (membrane proteins 
mitofusin 2). Western blot analysis revealed a significant increase 
of Drp1 expression, a decrease of inhibitory p-Drp1 (Ser637) as 
well as the ratio of p-Drp1 (Ser637)/Drp1 and a slight increase of 
Fis1 in the PS1-E120K group compared with the control group 
(Fig. 6A~D). Furthermore, we found that the expression of OPA1, 
Mfn1 and Mfn2 was dramatically reduced in PS1-E120K group 
when compared with the control group (Fig. 6A, E, F and G). Q-
PCR analyses revealed dramatic increases of fission-related gene 
(DRP1) expression and decrease of fusion-related gene (Mfn1) 
expression in the PS1-E12K iPSC-derived neurons compared with 
the control neurons (Fig. 6J and K). In addition, mitophagy-related 
proteins PINK1 and PARKIN showed dramatic increase in the 
PS1-E120K cells compared with the control lines (Fig. 6A, H and I). 
These results strongly suggest that PSEN1 mutation may result in 
impaired mitochondrial fission and fusion.
Abnormal autophagy-related protein expression in the PS1-
E120K iPSC-derived neurons
Defective autophagy function is known also to occur in AD 
which correlates with the presence of neuritic plaques and fila-
mentous tau [25, 26]. It was previously shown that PS1 is neces-
sary for the degradation of abnormal proteins using autophagy-
lysosome system [27]. To investigate this further in our neurons, 
we measured the expression levels of autophagy-related proteins, 
including Ubiquitin (Ub), p62 (SQSTM1, sequestosome 1; cargo 
protein marker), Beclin1 (autophagosome membrane formation-
related protein), LC3b (light chain 3; autophagosome formation 
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Fig. 4. Increase of Aβ deposits in the PS1-E120K iPSC-derived neurons, examined at 6 and 10 weeks after neuronal differentiation. ELISA detection of 
Aβ42 (A) and Aβ40 (B) secreted from the PS1-E120K iPSC-derived neurons into the medium (extracellular), which was measured at 48 hours after the 
last medium change. Levels of Aβ42 (A) and the ratio of Aβ42/ Aβ40 (C) showed a dramatic increase in the PS1-E120K iPSC-derived neurons at both 6 
and 10 weeks of neuronal differentiation. Intracellular Aβ42 (D) and Aβ40 (E) levels were measured in a total of 1 µg proteins from 10 week-differentiated 
neurons. Levels of the intracellular Aβ42 (D) and the ratio of Aβ42/Aβ40 (F) showed a significant increase in the PS1-E120K iPSC-derived neurons. (G, H) 
Detection of Aβ deposits using an antibody against 6E10 (shown in green) co-stained with MAP2 (red) (G) or using an antibody against 4G8 (shown in 
red) co-stained with and TUJ1 (green) (H) and DAPI (blue) at 10 weeks of neuronal differentiation. The bottom panels show the z-stack images of the 
6E10 and 4G8-positive Aβ deposits (arrows) in the PS1-E120K iPSC-derived neurons. Scale bar: 10 µm. (I, J) Western blot analysis showing a significant 
increase of total APP expression levels in the PS1-E120K iPSC-derived neurons compared to the control. Representative ELISA, western blot and ICC 
images were obtained from three independent experiments.
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Fig. 5. Elevated p-tau levels in the PS1-E120K iPSC-derived neurons. (A~C) Western blot analysis showing a significant increase of phosphorylated tau 
(p-tau) including AT8, AT180 and p-Tau (Ser400, Thr403/ Ser404) and total tau (t-tau, Tau5) proteins in the PS1-E120K iPSC-derived neurons com-
pared with the control group. (D~F) Quantification of the western blots on the expression of AT8 (D), AT180 (E) and p-Tau (F) showing a significant 
increase of the expression of each in the PS1-E120K iPSC-derived neurons. (G) Immunocytochemical analysis showing the expression of AT8 (red) 
and MAP2 (green), counter-stained with DAPI (blue), in the PS1-E120K iPSC-derived neurons at 10 weeks of neuronal differentiation. Note that PS1-
E120K iPSC-derived neurons exhibit a dramatic increase of phosphorylated-tau (AT8) both in the soma (arrow) and neurites (arrowhead) compared 
with the control group. Scale bar: 10 µm. (H~J) Quantification of the immunocytochemical analysis on the expression and localization of AT8 proteins 
with respect to MAP2-positive neurons. MAP2 expression was normalized against DAPI (G), whereas AT8 expression was normalized against MAP2 
expression (I, J). Note that significant increase of AT8 expression both in the soma (I) and neurite (J) regions in the PS1-E120K iPSC-derived neurons. 
Representative western blot and ICC images were obtained from three independent experiments.
361www.enjournal.orghttps://doi.org/10.5607/en.2018.27.5.350
iPSC Modeling of AD with PSEN1 Mutation
marker) and LAMP2 (lysosome-associated membrane proteins). 
Western blot analysis revealed that the expression levels of Ub 
and LC3b-II (active form of LC3b), but not p62, were significantly 
increased in PS1-E120K iPSC-derived neurons (Fig. 6L, M and 
P). To further investigate LC3B expression at the cellular level, we 
performed immunocytochemical analysis and found that PS1-
E120K iPSC-derived neurons exhibit a dramatic increase of LC3b 
in the periphery of soma area, compared with the control group 
(Fig. 6R). In contrast, the chaperone-mediated autophagosome 
and lysosome membrane marker, LAMP2 showed a dramatic de-
crease in the PS1-E120K iPSC-derived neurons (Fig. 6L and Q). To 
further investigate the dysfunctioning autophagy, we performed 
autophagy flux assay with treatment of 10 uM chloroquine (CQ), 
a compound known to interfere with the lysosomal function. 
Fig. 6. Impaired balance of mitochondria 
fission and fusion along with defective au-
tophagy in the PS1-E120K iPSC-derived 
neurons. (A) Representative western blot 
image from three independent experi-
ments. (B~I) Quantification of marker 
proteins associated with mitochondrial 
fission (Drp1, p-Drp1 and Fis1) and fu-
sion (OPA1, Mfn1and Mfn2). Note that 
fission-related proteins were increased, 
whereas fusion-related proteins were de-
creased in the PS1-E120K cells compared 
with the control cells. Mitophagy-related 
protein PINK1 and PARKIN showed 
dramatic increases in the PS1-E120K cells 
compared with the control cells. (J~K) Q-
PCR analysis revealing the mRNA expres-
sion of fission and fusion-related genes 
in 10 weeks differentiated neurons from 
iPSCs. (L) Representative western blot im-
age from three independent experiments. 
(M~Q) Quantification of the expression 
of ubiquitination (Ub) and autophagy-
related proteins (p62, Beclin1, LC3B, 
LAMP2). Note that levels of Ub and LC3B 
were significantly increased, whereas the 
LAMP2 signal was significantly decreased 
in the PS1-E120K iPSC-derived neurons. 
(R) Immunocytochemical staining show-
ing the expression of LC3b (red) and 
DAPI (blue) in both iPSC-derived neu-
rons at 10 weeks of neuronal differentia-
tion. Note that PS1-E120K iPSC-derived 
neurons exhibit a dramatic increase of 
LC3b in the periphery of soma area (ar-
row), compared with the control group. (S) 
Autophagy flux assay showing a signifi-
cant increase in LC3B-II expression after 
treatment with 10 uM chloroquine (CQ) 
in the PS1-E120K iPSC-derived NPC 
compared with the control. (T~P) CytoID 
(green) stained with DAPI (blue) after CQ 
treatment showing a dramatic increase in 
number of autophagic vesicles in the PS1-
E120K iPSC-derived NPC compared with 
the control. Representative western blot 
and ICC images were obtained from three 
independent experiments. Scale bar: 10 
µm.
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Autophagy flux assay showed a significant increase in LC3B-II ex-
pression after the CQ treatment in the PS1-E120K iPSC-derived 
NPC compared to the control (Fig. 6S). In addition, we performed 
the live cell staining with CytoID. In line with previous findings, 
the PS1-E120K iPSC-derived NPCs exhibited dramatic increases 
in the number of autophagic vesicles compared with the control 
cells (Fig. 6 T~P). Taken together, these results strongly suggest that 
PSEN1 mutation alters autophagic activity and lysosomal expres-
sion in the differentiated neurons.
DISCUSSION
To better understand AD pathogenesis, we have utilized iPSC 
technology and established two iPSC lines, one harboring PS1-
E120K mutation and one from a normal control. We did not use 
an isogenic control for two reasons; (i) the technical difficulty 
of doing this in the context of this specific mutation and (ii) the 
desire to look at aged control cells to exclude aging effects as the 
main pathological component of any disease pathogenic pathway 
that we identified in our mutation cell line.
We found that neurons so derived from the mutant cell line had 
the following characteristics. First, cortical neurons expressing 
TBR1+ and CTIP2+ and cholinergic neurons expressing ChAT+ 
were differentiated from both iPSC lines with no obvious differ-
ences in the differentiation propensity of the cell lines, nor any 
major morphological differences in the neurons so derived from. 
Second, the PS1-E120K iPSC-derived neurons exhibited higher 
levels of Aβ42, an altered Aβ42/Aβ40 ratio, and Aβ deposition com-
pared with the iPSC-derived neurons developed from a normal 
elderly subject. Third, the levels of phosphorylated tau and its 
deposition in dendrites and cell bodies was seen only in the PS1-
E120K iPSC-derived neurons. In line with previous studies dem-
onstrated that increased Aβ42/40 ratio can lead increase in levels 
of p-Tau through GSK3β activation in AD patient iPSC-derived 
neurons [20, 21], we deduced that PS1-E120K mutation can result 
in increased Aβ42/40 ratio and subsequent tau phosphorylation 
through the GSK3β activation. We have observed the same find-
ings in another iPSC line generated from a patient carrying a dif-
ferent PSEN1 mutation (S170F), which exhibited a very similar 
pathophysiology as in the PS1-E120K iPSC line (data not shown). 
This new line also exhibited a very similar AD-related phenotypes, 
including increased levels of Aβ and p-Tau (AT8); impaired bal-
ance of mitochondrial fission and fusion; and abnormal expres-
sion of autophagy-related proteins. Given that similar AD patho-
physiology can be observed from two independent PSEN1 iPSC 
lines, it will be likely that the results obtained from PS1-E120K 
iPSC line can truly represent the pathophysiology of AD patients 
carrying PSEN1 mutations.
There have been several recent studies on the establishment 
and characterization of PSEN mutant iPSC lines, but they are 
mainly focused on the increase of Aβ and Tau [26, 28]. However, 
the present study investigated on not only Aβ and Tau levels but 
also mitochondria and autophagy defects. Mitochondria is a 
highly dynamic organelle and the intracellular population at any 
one time derives from a balance between fission and fusion [22]. 
Western blot analysis revealed that fission associated markers 
were increased, whereas fusion related markers were markedly 
decreased in PS1-E120K iPSC-derived neurons compared with 
the control iPSC-derived neurons. As extracellular Aβ and phos-
phorylated tau are implicated in mitochondrial fission and fusion 
in humans [8, 24], we speculated that the increased secretion and 
aggregation of Aβ and phosphorylated forms of tau protein caused 
this imbalance of mitochondrial fission and fusion. Because mito-
chondrial fission is associated with autophagy and the genesis and 
degradation of autophagosomes [29], we thought the increase in 
mitochondrial fission may affect the clearance of pathologic pro-
tein accumulation through this pathway and this is what we found. 
Finally, given that the iPSC lines we generated were from a young 
donor, the changes in function of mitochondira and autophagy 
that we see must relate to the mutation and not an old cell.
There are many reports suggesting the possibility of defective au-
tophagy in AD. It has been demonstrated that autophagy vacuoles 
(AVs) accumulate in human AD brains and are related to the pres-
ence of neuritic plaques and filamentous tau [25, 28]. Furthermore, 
PS1 knockout mice showed a dysfunction of autophagy-lysosome 
system, including increase of LC3B and decrease of LAMP2 [27]. 
In this study, we observed significantly increased Ub and active 
forms of LC3b-II in the PS1-E120K iPSC-derived neurons, which 
strongly suggests that PS1-E120K mutation can induce impaired 
function of lysosome and the subsequent accumulation of AVs. In 
addition to the role of overproduction of Aβ through APP cleav-
age, PSEN1 mutations have an important function as a chaperone 
for the vacuolar-ATPase to acidify the lysosomal lumen [26, 28]. 
We showed that the expression of LAMP2, a Chaperone-mediated 
autophagosome and lysosomal membrane marker, was dramati-
cally decreased in the PS1-E120K iPSC-derived neurons. These 
results point towards their being abnormal autophagy activity and 
altered lysosomal expression in patients with PSEN1 mutation.
It should be stressed that there are several limitations to our 
study. First, the pateint and the elder sister of the patient had cer-
ebellar atrophy and cerebellar symptoms and signs. Nevertheless, 
we were not able to further differentiate iPSC-derived neurons 
into Purkinje cells to evaluate relevant changes. Second, although 
the patient has a family history of dementia and cerebellar ataxia, 
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the pedigree did not fit to an autosomal dominant patterns of 
inheritance. Thus, the patient may have a de novo  mutation of 
PS1-E120K. Third, the normal elderly subject was older than the 
proband who provided the blood sample for the PS1-E120K iPSC 
generation, although this was deliberate for the reasons already 
stated and also explains why we did not use an isogenic control. 
Subsequent studies with iPSCs obtained from subjects with simi-
lar ages and the same gender as well as from mutation carriers 
and non-carriers in the same family will provide more thorough 
information of the autosomal dominant AD iPSCs. Finally, we did 
not perform experiments to prove any causal relationship between 
Aβ/tau formation and the dysfunction we found in mitochondria 
and autophagy. We observed changes of some autophagy-related 
proteins, such as LC3B and LAMP2, but no significant changes of 
p62 expression were observed.
In summary, we have shown that a PSEN1 patient with an E120K 
mutation has major abnormalities in terms of the iPSC-derived 
neurons so derived from them. These abnormalities include all 
the typical pathological findings of AD such as increased Aβ and 
tau, as well as impaired mitochondrial function and abnormal 
autophagy activity. As such our approach will provide unique in-
sights into the pathogenesis of autosomal dominant forms of AD 
and with this the possibility of developing new therapies.
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